|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Departments of Biochemistry, Pathology, and
Medicine, and the Division of Hematology, University of Washington,
Seattle, WA.
Mice that lack the matricellular angiogenesis inhibitor,
thrombospondin-2 (TSP2), display a bleeding diathesis, despite normal blood coagulation and the lack of thrombocytopenia. Although platelets do not contain detectable levels of TSP2, TSP2-null platelets are
compromised in their ability to aggregate in vivo in response to
denudation of the carotid artery endothelium, and in vitro following
exposure to adenosine diphosphate (ADP). Megakaryocytes (MKs)
show high levels of TSP2 by immunohistochemical analysis of
bone marrow. However, when cultured in vitro, MKs contain little TSP2
protein or mRNA. These findings suggest that most TSP2 is acquired from
the bone marrow microenvironment. Consistent with this hypothesis, MKs
take up recombinant TSP2 in an integrin-dependent manner when it is
supplied in the culture medium. Furthermore, uptake of TSP2 in vitro
affects MK differentiation and proplatelet formation. The functional
significance of this process is supported by the presence of
ultrastructural abnormalities in TSP2-null bone marrow, including
extensive fragmentation of the peripheral zone in MKs and failure of
this zone to form close associations with vascular sinuses. We conclude
that the uptake of TSP2 by MKs from the marrow milieu is required for
proper MK function and the release of functionally competent platelets.
(Blood. 2003;101:3915-3923) Thrombospondin-2 (TSP2) is a potent
inhibitor of angiogenesis that participates in the processes of
development and tissue repair.1 Specifically, TSP2 is
expressed during embryonic development, and during healing of dermal
wounds and the foreign body response to implanted
biomaterials.2-5 In addition, TSP2 has been implicated in
the process of tumor growth where it has been shown to inhibit blood
vessel formation and limit the growth of squamous cell
carcinomas.6 As a matricellular protein, TSP2 can interact
with both cell-surface receptors and extracellular matrix (ECM)
components and is believed to function as a modulator of cell-matrix
interactions.7
We have previously shown that mice that lack TSP2 develop a pleiotropic
phenotype characterized by connective tissue abnormalities that include
abnormal collagen fibrillogenesis.8 In addition, these
mice display increased angiogenesis, increased bone formation, reduced
fibroblast adhesion, and an unexpected bleeding diathesis. We
hypothesized that the latter could result from an intrinsic qualitative
platelet defect, from a subendothelial defect, or both. While we have
preliminary evidence for the contribution of a connective tissue
abnormality to the bleeding diathesis ("Discussion"), we were
surprised to find a reproducible defect in aggregation in the response
of TSP2-null platelets to a mild agonist. Since TSP2, unlike TSP1, is
not present in platelets we hypothesized that the abnormality might
arise earlier, during megakaryocyte (MK) development.
Proplatelets are long processes that issue from the surface of fully
mature MKs, migrate through the endothelial barrier of marrow
sinusoids, and fragment into platelets. At the molecular level, little
is understood regarding the regulation of these events, except that
The mode of action of TSP2 in the regulation of cell adhesion is just
beginning to be elucidated, and much of our current understanding
originates from the analysis of the adhesive defect in TSP2-null
fibroblasts.8 These cells have a 2-fold increase in matrix
metalloproteinase 2 (MMP2) that is responsible for their compromised
adhesion.16 TSP2 can bind MMP2 and direct it to the
lysosomes by interacting with one of its receptors, low-density lipoprotein receptor-related protein.17 We have also shown
that TSP2 can modulate the levels of MMP2 in vivo during the formation of sponge granulomas.18 Since MKs contain
MMP219 it is possible that TSP2 may play a role in
modulating its levels in these cells.
To our knowledge, studies indicating that deficiency of a nonplatelet
protein can lead to the development of an intrinsic platelet defect
have not been previously reported. The present study focuses on an
examination of the origin of the intrinsic platelet abnormality in
TSP2-null mice and provides evidence for the uptake of TSP2 by MKs in
vitro as an important factor in normal MK and platelet function.
Animals
Platelet studies
Adenosine triphosphate (ATP) secretion was measured in whole blood in a lumi-aggregometer (Chrono-log). Samples of whole blood (900 µL) were incubated with 100 µL luciferin/luciferase reagent at 37°C for 30 seconds and stirred at 1000 rpm. Subsequently, ADP (20 µm) was added, and the ATP secretion tracings were recorded for 5 minutes. Denudation of the carotid artery Complete removal of the endothelium from the left carotid artery was achieved with a nylon thread as described previously.22,23 Mice were perfuse-fixed 10 minutes following injury and the carotid artery was removed, fixed, and processed for either scanning electron microscope (SEM) or tranmission electron microscope (TEM), as described previously.24Reverse transcriptase-polymerase chain reaction (RT-PCR) Reverse-transcribed (Superscript II; GIBCO BRL, Carlsbad, CA) RNA, purified from MKs (next section) with an Rneasy kit (Qiagen, Valencia, CA), was a kind gift of Dr Yoshitaka Miyakawa (University of Washington). PCR amplification with TSP2-specific primers was performed as described previously.16 Amplification of ribosomal protein S6 cDNA, as described previously,25 served as internal control. The mRNA origin of the observed band was confirmed by its resistance to DNAse digestion of the RNA prior to amplification.Studies of MKs in vitro Mice were injected (2 µg/d; 5 days) with human thrombopoeitin (TPO; Zymogenetics, Seattle, WA). MKs were cultured at 37°C in Iscove modified Dulbecco medium/1% Nutridoma/50 ng/mL TPO and were then purified over a discontinuous bovine serum albumin (BSA) gradient, as previously described prior to use.10 Subsequently, MKs were cultured with or without 10% plasma.To examine TSP2 uptake, 1 × 103 MKs/well were plated in 16-well glass chamber slides (Nunc, Rochester, NY) and recombinant TSP2 (rTSP2; 10 µg/mL) was added one hour after plating. To block rTSP2 uptake, MKs were plated and either the arginine-glycine-aspartic acid (RGD)-containing peptide (GRGDTP; 50 µm) or a control peptide (YVGVAPG; 50 µm) was added to the cultures 2 hours prior to the addition of rTSP2. Then, 24 hours later, the culture media were removed and the cells were washed with phosphate-buffered saline (PBS) and fixed with 2% paraformaldehyde for 30 minutes at RT. The wells were then washed with PBS, blocked with 1% BSA/0.1% Triton X-100/PBS for 30 minutes and then incubated with rabbit anti-TSP2 antibodies. Fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit immunoglobulin G (IgG) was used to detect TSP2 in MKs. Both rTSP2 and the rabbit anti-TSP2 antibodies have been described.2 For confocal microscopy, MKs were isolated, plated, and treated with rTSP2 (10 µg/mL) in the presence or absence of 10% plasma. Following a 48-hour incubation, MKs were washed, fixed in 3.7% paraformaldehyde, and permeabilized with 0.2% Triton X-100. TSP2 was detected with FITC-conjugated IgG. Nuclei were visualized with DAPI (4,6 diamidino-2-phenylindole). FITC was collected with an argon laser, and DAPI with 2 photon excitation on a Leica TCS SP/MP confocal microscope (Heidelberg, Germany). To examine the effect of TSP2 on proplatelet formation, we added TSP2 to MKs cultured in the absence of plasma, as described above. Then, 24 hours later, the medium was removed and the cells were washed gently with PBS. Medium containing 10% plasma was then added for 48 hours to induce MK differentiation. Cell viability and proplatelet formation were assessed as described previously.10 The latter was determined by examination of cultures under phase contrast. The cells were then fixed and examined. All experiments were performed in triplicate. Bone marrow immunohistochemistry and electron microscopy Bone marrow plugs were flushed with saline from femurs of 3-month-old TSP2-null and wild-type mice that had been killed. Plugs were embedded in optimum cutting temperature (OCT) compound and used to generate cryosections. To immunolocalize TSP1 and TSP2, sections were fixed with acetone for 10 minutes at 20°C and then air-dried for one hour. Following washing, TSP1 and
TSP2 were visualized as described in the previous section. The
antimouse TSP1 antibody has been characterized3 and was a
kind gift of Dr D. Mosher, University of Wisconsin. To visualize and
quantify MKs in bone marrow, formalin-fixed decalcified femurs
(Accumate RDO rapid decalcifying solution; Sigma) were
embedded in paraffin, and sections were stained with an anti-VWF
antibody (DAKO, Carpinteria, CA) according to the supplier's
instructions. For electron microscope (EM) analysis, bone
marrow plugs were placed in ice-cold Karnovsky fixative and processed
for analysis as described previously.26,27
TSP2-null platelets fail to form aggregates in vivo To examine the ability of TSP2-null platelets to form aggregates following vascular injury, the endothelium of the left common carotid artery of anesthetized mice was denuded by the insertion and rotation of a flexible nylon loop. Circulating platelets were allowed to interact with the exposed subendothelium for 10 minutes, and the arteries were then perfused-fixed in situ, harvested, processed, and analyzed by SEM and TEM. SEM analysis revealed the formation of numerous platelet aggregates on the exposed subendothelium of wild-type animals (Figure 1A). These aggregates ranged in size from 10 to 75 µm in diameter. On the contrary, large platelet aggregates, over 10 µm in diameter, were absent from the exposed subendothelium of TSP2-null mice (Figure 1B), although we observed many single platelets as well as small platelet aggregates. This observation suggests that the adhesion of platelets to the exposed subendothelium was not primarily compromised. In experiments in which the carotid arteries were harvested 15 minutes following denudation, we observed that larger platelet aggregates were beginning to form in TSP2-null mice, but these aggregates were still significantly smaller than those in wild-type mice (data not shown). Thus, we conclude that conditions in TSP2-null mice led to a delay in platelet aggregation.
To better examine the interaction of platelets with the exposed
subendothelium we analyzed denuded arteries by TEM. By this method we
observed numerous aggregates in wild-type mice that involved a layer of
flattened and activated platelets adhering to the subendothelium,
covered by layers of closely adherent platelets (Figure
2A). TSP2-null subendothelia mostly
lacked such aggregates, and only occasional small aggregates,
consisting of loosely organized platelets and displaying minimal
cell-cell interactions, were present (Figure 2B). The lack of intimacy
in the interactions of TSP2-null platelets was in marked contrast to
the extensive and close interactions displayed by wild-type cells.
Consistent with our findings with SEM, numerous flattened platelets
adhering to the subendothelium could be observed in TSP2-null mice.
These findings suggest that platelet aggregation is compromised in
TSP2-null mice and provide a basis for the bleeding diathesis in these
animals. However, the denudation experiments do not distinguish between a subendothelial matrix abnormality and an intrinsic platelet defect.
We proceeded to examine the latter possibility by analyzing platelet
function ex vivo.
TSP2-null platelets are deficient in aggregation and secretion in vitro PRP, prepared from wild-type and TSP2-null mice, was analyzed by aggregometry after exposure to the platelet agonists, thrombin, collagen, or ADP. Initial analysis was performed in microtiter wells to minimize the required amount of blood. Of the 3 agonists tested, only aggregation in response to ADP was compromised in TSP2-null platelets (Figure 3A). During the early (30-second) response to ADP, TSP2-null and wild-type platelets displayed similar aggregation, but the final level of aggregation of TSP2-null platelets was only 40% of normal. The response to thrombin and collagen was indistinguishable between TSP2-null and wild-type platelets (data not shown). In addition, similar levels of P-selectin on TSP2-null and wild-type platelets were observed by fluorescence-activated cell-sorter (FACS) analysis, following exposure of whole blood to thrombin (data not shown). These results demonstrate that TSP2-null platelets are compromised in their aggregative response to ADP and suggest the existence of an intrinsic platelet defect.
To exclude the possibility that TSP2-null plasma affected aggregation, we proceeded to analyze platelet function in washed platelets. We used standard aggregometric measurements instead of microtiter wells and a plate-reader, since the latter can provide measurements only at 30-second intervals. Analysis of TSP2-null platelets revealed that the response to ADP was again less than half maximal in comparison with wild-type platelets (Figure 3B). Furthermore, ATP secretion following exposure of whole blood to ADP was compromised in TSP2-null platelets (Figure 3C). TSP2-null platelets appeared to respond normally to thrombin and collagen, and in response to the latter showed the characteristic initial reduction in transmittance due to the induced change in cell shape. Dilution of collagen did not compromise their responses (data not shown). TSP2 is lacking in platelets Since the presence of TSP2 in wild-type platelets had not been assessed previously, we examined this issue. Using anti-TSP1- and anti-TSP2-specific antibodies, we observed high levels of TSP1 (Figure 4A) but no TSP2 (Figure 4B) in wild-type platelets mildly activated with thrombin. The same anti-TSP2 antibody has been used successfully to detect TSP2 in bone marrow stroma cells (BMSCs),28 skin fibroblasts,16 and in MKs (Figure 5A). We were also unable to detect TSP2 in platelet lysates by Western analysis (data not shown). Analysis of TSP2-null platelets by the same techniques revealed no changes in the levels of TSP1 (data not shown). This finding is consistent with previous observations that indicate the lack of compensatory up-regulation of TSP1 in TSP2-null mice. In addition, TSP2-null platelets, analyzed by FACS, displayed surface levels of 2 and IIb 3 integrins that were similar to those of wild-type platelets (data not shown).
TSP2 is present in MKs in vivo Immunohistochemical staining of wild-type bone marrow cryosections with anti-TSP2 antibodies revealed the presence of strong immunoreactivity in MKs, and weaker immunoreactivity in the bone marrow stroma (Figure 5A). Consistent with previous demonstrations,29,30 MKs were also immunoreactive for TSP1 (Figure 5B). Similar observations were made in formalin-fixed, paraffin-embedded sections from wild-type, decalcified femurs (data not shown). No changes in TSP1 immunoreactivity and no TSP2 immunoreactivity were observed in TSP2-null bone marrow (data not shown). However, the distribution of TSP1 and TSP2 in MKs was different, with the former predominantly in the cytoplasm, presumably membrane-bound (Figure 5B), and the latter prominent in the periphery of the cell. In addition, contrary to TSP1, TSP2 was present only in a subset of MKs (approximately 30% of the MKs that exhibited immunoreactivity to TSP1 and VWF), suggesting that its presence in these cells may be dependent on their stage of maturation. We also quantified the number of MKs in TSP2-null and wild-type mice, following visualization of MKs by antibodies to VWF. The number of MKs in TSP2-null marrow (4.5 ± 1.8 MKs per 0.04 µm2; n = 5) was similar to that in control marrow (4.8 ± 2.1 MKs per 0.04 µm2; n = 5). To better understand the role of TSP2 in MK biology and platelet function we initiated studies of wild-type MKs in vitro.Uptake of TSP2 by MKs in vitro MKs, purified from the femurs of wild-type TPO-treated mice, were expanded in culture and analyzed for TSP2 expression by immunocytochemistry and RT-PCR. Very weak TSP2 staining, which was slightly higher than background, was observed in MKs cultured in the absence of plasma (Figure 6A). Analysis of MK RNA by RT-PCR with TSP2-specific primers revealed the presence of a minor band that migrated at the expected molecular weight of 539 bp (MK, inset in Figure 6A). A positive control was generated by amplifying dermal fibroblast-derived RNA (Fb, inset in Figure 6A). These observations were inconsistent with the high levels of TSP2 that were detected in MKs in vivo. Thus, we postulated that the source of TSP2 in MKs in vivo might be exogenous. To test this hypothesis we added rTSP2 to MKs grown in vitro and were able to detect a dramatic increase in their immunoreactivity by immunocytochemistry with anti-TSP2 antibodies (Figure 6B). This finding suggests that MKs are able to take up TSP2 from their extracellular environment. Uptake was dependent on integrin function and generation of ATP, since preincubation of MKs with an RGD-containing peptide inhibited the uptake (Figure 6C), and uptake was also inhibited by preincubation of MKs at 4°C (data not shown). A non-RGD control peptide had no effect on uptake (Figure 6D). Furthermore, culture of MKs in the presence of plasma, a condition shown to induce proplatelet formation and platelet release, also reduced the uptake of TSP2, and in this case TSP2 appeared to be associated with the cell membrane (Figure 6E). Proplatelet-forming MKs were observed in these cultures but they did not display immunoreactivity for TSP2 (Figure 6F). The latter finding suggests that either TSP2 is not taken up by MKs under conditions that induce their maturation or that mature MKs, those that can make proplatelets, have lost their TSP2.
To verify that addition of rTSP2 in vitro leads to intracellular uptake in MKs, we analyzed rTSP2-treated MKs by confocal microscopy. Permeabilized MKs, cultured in the absence of 10% plasma, were stained with anti-TSP2 antibodies and nuclei were visualized with DAPI. Analysis of images obtained from the plane of the nuclei confirmed the intracellular location of TSP2 (Figure 6G-H). The distribution of the protein was well within the cytoplasm of MKs and close to the nuclei, indicating that rTSP2 was internalized. On the contrary, the appearance of TSP2-specific immunoreactivity in MKs treated with rTSP2 in the presence of plasma was predominantly peripheral (not shown). TSP2 limits MK differentiation and proplatelet formation To investigate the significance of the uptake of TSP2 on MK differentiation and vice versa, we asked whether MKs that have taken up TSP2 could undergo proplatelet formation if they were placed in media containing 10% plasma. In addition, we determined whether addition of 10% plasma could reduce the number of MKs that contain TSP2. Immunocytochemical staining of these cultures with anti-TSP2 antibodies (to detect TSP2) and phalloidin (to detect the actin cytoskeleton) indicated that the presence of TSP2 correlated negatively with differentiation of MKs (Figure 7A-B). Thus, all cells that exhibited actin bundling, an event that precedes proplatelet formation, were devoid of TSP2 (Figure 7B). Similarly, all cells that exhibited TSP2 immunoreactivity did not have a bundled cytoskeleton (Figure 7A). Furthermore, none of the MKs that formed proplatelets were immunoreactive for TSP2 (Figure 7B). These results suggest that the uptake of TSP2 is limited to nonproplatelet-forming MKs. To determine whether TSP2 had a quantifiable, limiting effect on proplatelet formation, we determined the percentage of MKs that reached the proplatelet formation stage with or without exposure to TSP2. Because the detection of proplatelet-forming MKs from fixed and stained samples is not quantitatively reliable, we analyzed MK cultures by phase-contrast microscopy at 24 and 48 hours following treatment. As shown in Figure 7C, addition of TSP2 significantly reduced, or delayed, the number of MKs that were able to undergo proplatelet formation. It should be noted that this experiment could be followed only for a period of 72 hours, since MKs do not survive in culture beyond this time point. However, estimation of cell viability indicated that it was not affected by exposure to TSP2 (data not shown). Moreover, exposure of MKs containing TSP2 to 10% plasma caused a reduction in the number of these proplatelet-forming cells within 48 hours. Specifically, the number of MKs containing TSP2 was reduced from 74 ± 6.2% to 37.5 ± 12.9% (P .05) when exposed to plasma,
suggesting that TSP2 is lost from cells undergoing differentiation
(Figure 7D).
Ultrastructural abnormalities in TSP2-null MKs Ultrastructural analysis of TSP2-null MKs in bone marrow plugs by TEM revealed 2 major abnormalities that are prominent in all the sections. First, many TSP2-null MKs displayed extensive fragmentation of their peripheral clear zones (Figure 8B). Normally, the peripheral zones of MKs are continuous, as is observed in wild-type cells (Figure 8A). Furthermore, the peripheral zone of TSP2-null MKs, unlike that of wild-type MKs, failed to form an intimate association with the subendothelial component of vascular sinuses (Figure 9A-B). Instead, the interaction of MKs with the vascular wall was limited to selected sites and was not extensive. These observations suggest that the abnormalities detected in the peripheral zones of TSP2-null MKs may have a negative influence on the interaction of MKs with vascular sinuses. Interestingly, we were able to observe proplatelets in the vascular lumen of TSP2-null marrow, suggesting that ultimately their release is not compromised (data not shown). Furthermore, as noted originally,8 the number of platelets in the circulation of TSP2-null mice is, if anything, increased.
Our investigation into the basis for the bleeding diathesis in the TSP2-null mouse has yielded the surprising finding that TSP2-null platelets have an intrinsic defect in aggregation, despite the fact that normal platelets lack TSP2. Aggregation was compromised in response to a mild agonist, ADP, but was normal when platelets were treated with thrombin or collagen. As a possible reflection of this defect, we observed that platelets adhered to the vessel wall but did not aggregate normally when the carotid artery endothelium was denuded in the TSP2-null mouse. In searching for the basis for the intrinsic platelet defect, we discovered that normal MKs synthesize small amounts of TSP2 in vitro, but take up a far larger proportion in an integrin-dependent manner when the recombinant protein is added to the culture medium. We speculate that a similar process occurs in vivo since a subset of MKs stain strongly with an antibody to TSP2, and BMSCs actively synthesize and secrete the protein into the bone marrow microenvironment. In addition, TSP2-null MKs display fragmentation of peripheral zones and loss of close associations with vascular sinuses, which we presume reflect the lack of TSP2. The uptake and subsequent loss of TSP2 from MKs The endocytic uptake of a number of proteins from plasma by MKs has been documented31-33 and in the case of fibrinogen involves an integrin.34 The storage of proteins, such as factor V and fibrinogen, in granules ensures that these proteins will be available during platelet activation. However, there is no precedent for the uptake of proteins by MKs that are subsequently lost in the formation of platelets. Since MKs express low levels of TSP2 it is unclear why these cells should take up additional TSP2 from the extracellular milieu, rather than increase endogenous synthesis. Perhaps the synthesis and uptake of TSP2 is regulated by a variation in receptor levels during maturation of MKs. Such regulation has been demonstrated for glycoprotein VI (GPVI) and21 during expansion of
MKs.35-37 Partial support for the hypothesis that the
uptake of TSP2 is dependent on the temporal availability of surface
receptors may be found in our results that demonstrate the ability of
plasma to influence this process. Specifically, when MKs were cultured in media containing plasma, the distribution pattern of TSP2 was predominantly peripheral. The pattern perhaps better reflects the
situation in vivo, and is consistent with the suggestion that TSP2 may
localize to the peripheral zone.
Previously we have shown that TSP2-null mice have increased numbers of BMSCs,38 and recently we have determined that BMSCs are a major source of TSP2 in the bone marrow.28 The influence of BMSCs on MKs has been demonstrated by coculture studies in which these cells were shown to induce MK growth and proplatelet formation by secreting TPO and stroma derived factor-1.39-41 However, the paracrine effects of BMSCs on the maturation of MKs and proplatelet formation are rendered ineffective when BMSCs and MKs are in direct contact. We have initiated in vitro studies to investigate whether the effect of TSP2-null BMSCs and their conditioned media on wild-type MKs differs from that of their control counterparts. The mechanism by which TSP2 is lost from MKs as they form platelets remains unknown. Our in vitro studies suggest that MKs that have taken up TSP2 proceed to lose it when induced to differentiate. A possible explanation for how this loss could occur in vivo may be the targeted localization of TSP2 to the peripheral zone of the MKs, since this zone is excluded from platelet formation.42,43 TSP2 may function in the peripheral zone to assist the MKs in migrating to and interacting with the sinusoidal subendothelium during proplatelet formation. Significance of the abnormalities in TSP2-null platelets The inability of TSP2-null platelets to respond fully to ADP is consistent with the observation that these cells can adhere and spread on an exposed subendothelium but fail to form large aggregates. The latter process depends on the release of ADP from the granules of activated platelets, which appears deficient in TSP2-null platelets. This finding is also supported by the suboptimal release of ATP from ADP-activated TSP2-null platelets. We have therefore initiated studies to investigate the response of TSP2-null platelets to ADP in greater detail. We are interested in determining whether all ADP-induced signaling pathways are intact and whether the levels of the 2 known ADP receptors are normal. ADP induces platelet aggregation by binding purinergic receptors such as P2Y1 and P2Y12.44,45 P2Y1 is responsible for mobilization of ionized calcium from internal stores and for initiation of aggregation. The recently discovered ADP receptor, P2Y12, couples to Gi to reduce adenylyl cyclase activity and is essential for the full aggregation response to ADP. Thus, determination of the extent to which these processes are altered in TSP2-null platelets should permit the identification of the basis for possible deficiencies in ADP-induced aggregation.Other defects in platelet formation from MKs The process of platelet release from MKs by fragmentation at the ends of proplatelet processes has been observed in vitro in an elegant study.46 However, the interpretation of this study was limited because platelet release occurred in the absence of other cell types, such as endothelial cells, that are normally present in the marrow. Mori et al performed coculture experiments with endothelial cells and MKs in 3-dimensional collagen gels and were able to observe proplatelet formation by morphologic criteria.47 Platelet release has been shown to occur in the lung and spleen in a similar fashion.27,48 It is clear from such studies that MKs release proplatelets into the lumen of sinusoids. Despite the wealth of evidence demonstrating MK-vascular sinus interactions and proplatelet release, nothing is known about the molecules that regulate these events.It is clear, however, that abnormalities that originate in MKs can lead to the formation of platelets with compromised function. For example, deletion of the transcription factor, GATA-1, in mice led to structural abnormalities in MKs and a prolonged bleeding time.49 In addition, deletion of the transcription factor NF-E2 resulted in profound defects in MKs and severe thrombocytopenia.50,51 Although such studies provide a strong link between MK maturation and platelet function, at the molecular level little is understood about the actual processes involved. Since MKs expanded in vitro, where the levels of TSP2 are minimal, can undergo proplatelet release (Figure 6), we believe that this process is not dependent on TSP2. This conclusion is also supported by our observation of proplatelets in the vascular lumens of TSP2-null animals (T.R.K., unpublished data, June 2001). On the other hand, our in vitro studies suggest that TSP2 uptake may inhibit or delay platelet formation. Perhaps this may account for the 20% increase in circulating platelets in TSP2-null mice.8 How then do TSP2-null platelets acquire an intrinsic defect? Although we cannot provide an answer to this question, we speculate that the defect originates either in MKs during their transmural migration through vascular sinuses and/or in proplatelets during their release from MKs. Contribution of a matrix abnormality to the bleeding defect Since the aggregation defect in TSP2-null platelets is subtle, it may not account solely for the prolonged bleeding. Thus, the contribution of a subendothelial matrix abnormality should be considered. Exposed subendothelial collagen fibers have been shown to be the major inducer of platelet aggregation.52,53 In vitro studies have also shown that changes in the nature of collagen can alter its aggregative activity.54,55 Supporting evidence in vivo may exist in anecdotal reports that have linked bleeding diatheses with abnormalities in collagen fibrillogenesis in patients with the Ehlers-Danlos syndrome.56,57 In fact, analyses of the thrombogenicity of TSP2-null fibroblast-derived extracellular matrix indicate that it is compromised (F. Almus, T.R.K., P.B., and Z. Ruggeri, manuscript in preparation). It would be interesting to determine whether this deficiency extends to the subendothelial matrix. An analogous situation may exist in PECAM-1-null mice, in which prolonged bleeding times could not be corrected by bone marrow transplantation. This finding prompted the investigators to conclude that the defect was in endothelial cells.13How might the lack of TSP2 influence the thrombogenicity of cell-derived matrices in vitro and subendothelial matrices in vivo? In a number of studies we have reported that TSP2-null mice produce an abnormal matrix associated with defects in collagen fibrillogenesis.58 Furthermore, we have found that the solubility of dermal collagen in TSP2-null mice is 2-fold greater than in control animals (T.R.K., unpublished observation, May 2001). Thus, it seems possible that subendothelial collagen fibrils, which are altered in structure and in cross-linking, are present in TSP2-null mice and can influence the formation of platelet aggregates. The present study has revealed the existence of a complex mechanism that implicates TSP2 in platelet formation and function. TSP2, which is most likely produced by BMSCs in the bone marrow, is taken up by MKs and directed to the peripheral zone of these cells where it is required for their interaction with the matrix underlying the sinusoidal endothelium. A lack of TSP2 results in abnormalities in the ultrastructural appearance of the MKs and reduces the intimacy of their association with the vascular sinus. Consequently, TSP2-null mice form platelets that are intrinsically abnormal, as reflected in their reduced response to ADP and the marked reduction in their ability to form aggregates on an injured subendothelium. These findings provide a partial explanation for the bleeding diathesis in TSP2-null mice, and a novel resolution of the paradox of a genetically induced abnormality in a cell type that does not express the deleted gene product. Furthermore, our results highlight the functional importance of a matricellular protein, such as TSP2, in the bone marrow microenvironment, and emphasize the need to analyze cell-matrix interactions in this system in greater detail.
We thank Colleen Irvin for assistance with carotid artery denudations and Emily Stainbrook, Zhantao Yang, Henrik Andersen, and Dan Greenberg for assistance with platelet studies. We also thank Greg Priestley for assistance with FACS analysis and Brian Lanutti, Jonathan Drachman, and Norma Fox for assistance with the isolation of megakaryocytes. Confocal microscopy was performed with the assistance of the Keck Imaging Center, University of Washington. EM was performed with the assistance of the University of Washington EM Center and lumi-aggregometry with the assistance of the University of Washington Hospital Hematology Laboratory. We are indebted to Alan Nurdin, Paquita Nurdin, and Christel Poujol for assistance with the interpretation of EM images. Finally, we are indebted to Zaverio Ruggeri for helpful discussions and a critical reading of the manuscript.
Submitted November 9, 2001; accepted December 20, 2002.
Supported by the National Institute of Health grants HL 18645 and AR 45418.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Themis R. Kyriakides, Department of Biochemistry, Box 357350, University of Washington, Seattle, WA 98195; e-mail: themi{at}u.washington.edu.
1. Bornstein P, Armstrong LC, Hankenson KD, Kyriakides TR, Yang Z. Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol. 2000;19:557-568[CrossRef][Medline] [Order article via Infotrieve].
2.
Kyriakides TR, Zhu YH, Yang Z, Bornstein P.
The distribution of the matricellular protein thrombospondin 2 in tissues of embryonic and adult mice.
J Histochem Cytochem.
1998;46:1007-1015 3. Tooney PA, Sakai T, Sakai K, Aeschlimann D, Mosher DF. Restricted localization of thrombospondin-2 protein during mouse embryogenesis: a comparison to thrombospondin-1. Matrix Biol. 1998;17:131-143[CrossRef][Medline] [Order article via Infotrieve].
4.
Kyriakides TR, Leach KJ, Hoffman AS, Ratner BD, Bornstein P.
Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity.
Proc Natl Acad Sci U S A.
1999;96:4449-4454 5. Kyriakides TR, Tam JW, Bornstein P. Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol. 1999;113:782-787[CrossRef][Medline] [Order article via Infotrieve]. 6. Hawighorst T, Velasco P, Streit M, et al. Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. Embo J. 2001;20:2631-2640[CrossRef][Medline] [Order article via Infotrieve]. 7. Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest. 2001;107:929-934[CrossRef][Medline] [Order article via Infotrieve].
8.
Kyriakides TR, Zhu YH, Smith LT, et al.
Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis.
J Cell Biol.
1998;140:419-430 9. Schwer HD, Leucine P, Tiwari S, Italiano JE Jr, Hartwig JH, Shivdasani RA. A lineage-restricted and divergent beta-tubulin isoform is essential for the biogenesis, structure and funtion of blood platelets. Curr Biol. 2001;11:579-586[CrossRef][Medline] [Order article via Infotrieve].
10.
Rojnuckarin P, Kaushansky K.
Actin reorganization and proplatelet formation in murine megakaryocytes: the role of protein kinase calpha.
Blood.
2001;97:154-161
11.
Azam M, Andrabi SS, Sahr KE, Kamath L, Kuliopulos A, Chishti AH.
Disruption of the mouse mu-calpain gene reveals an essential role in platelet function.
Mol Cell Biol.
2001;21:2213-2220 12. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999;103:229-238[Medline] [Order article via Infotrieve].
13.
Mahooti S, Graesser D, Patil S, et al.
PECAM-1 (CD31) expression modulates bleeding time in vivo.
Am J Pathol.
2000;157:75-81
14.
Denis C, Methia N, Frenette PS, et al.
A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis.
Proc Natl Acad Sci U S A.
1998;95:9524-9529
15.
Patil S, Newman DK, Newman PJ.
Platelet endothelial cell adhesion molecule-1 serves as an inhibitory receptor that modulates platelet responses to collagen.
Blood.
2001;97:1727-1732
16.
Yang Z, Kyriakides TR, Bornstein P.
Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2.
Mol Biol Cell.
2000;11:3353-3364
17.
Yang Z, Strickland DK, Bornstein P.
Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2.
J Biol Chem.
2001;276:8403-8408
18.
Kyriakides TR, Zhu YH, Yang Z, Huynh G, Bornstein P.
Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of TSP2-null mice.
Am J Pathol.
2001;159:1255-1262
19.
Ogawa M, Kawamoto M, Yamanaka N.
Matrix metalloproteinase and tissue inhibitor of metalloproteinase in human bone marrow tissues
20.
Law DA, Nannizzi-Alaimo L, Ministri K, et al.
Genetic and pharmacological analyses of Syk function in alphaIIb beta3 signaling in platelets.
Blood.
1999;93:2645-2652
21.
Nieswandt B, Bergmeier W, Eckly A, et al.
Evidence for cross-talk between glycoprotein VI and Gi-coupled receptors during collagen-induced platelet aggregation.
Blood.
2001;97:3829-3835
22.
Lindner V, Fingerle J, Reidy MA.
Mouse model of arterial injury.
Circ Res.
1993;73:792-796 23. Lindner V, Reidy MA, Fingerle J. Regrowth of arterial endothelium: denudation with minimal trauma leads to complete endothelial cell regrowth. Lab Invest. 1989;61:556-563[Medline] [Order article via Infotrieve].
24.
Lindner V, Reidy MA.
Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries: an en face study.
Circ Res.
1993;73:589-595
25.
Armstrong LC, Bjorkblom B, Hankenson KD, Siadak AW, Stiles CE, Bornstein P.
Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism.
Mol Biol Cell.
2002;13:1893-1905 26. Lichtman MA, Chamberlain JK, Simon W, Santillo PA. Parasinusoidal location of megakaryocytes in marrow: a determinant of platelet release. Am J Hematol. 1978;4:303-312[Medline] [Order article via Infotrieve].
27.
Zucker-Franklin D, Philipp CS.
Platelet production in the pulmonary capillary bed: new ultrastructural evidence for an old concept.
Am J Pathol.
2000;157:69-74 28. Hankenson KD, Bornstein P. The secreted protein thrombospondin 2 is an autocrine inhibitor of marrow stromal cell proliferation. J Bone Miner Res. 2002;17:415-425[CrossRef][Medline] [Order article via Infotrieve].
29.
McLaren KM.
Immunohistochemical localisation of thrombospondin in human megakaryocytes and platelets.
J Clin Pathol.
1983;36:197-199
30.
Beckstead JH, Stenberg PE, McEver RP, Shuman MA, Bainton DF.
Immunohistochemical localization of membrane and alpha-granule proteins in human megakaryocytes: application to plastic-embedded bone marrow biopsy specimens.
Blood.
1986;67:285-293
31.
Camire RM, Pollak ES, Kaushansky K, Tracy PB.
Secretable human platelet-derived factor V originates from the plasma pool.
Blood.
1998;92:3035-3041
32.
George JN.
Platelet immunoglobulin G: its significance for the evaluation of thrombocytopenia and for understanding the origin of alpha-granule proteins.
Blood.
1990;76:859-870 33. Bricker LJ, Zuckerman KS. Serotonin uptake by progeny of murine megakaryocyte precursors (CFU-M) in vitro. Exp Hematol. 1984;12:672-675[Medline] [Order article via Infotrieve].
34.
Handagama P, Scarborough RM, Shuman MA, Bainton DF.
Endocytosis of fibrinogen into megakaryocyte and platelet alpha-granules is mediated by alpha IIb beta 3 (glycoprotein IIb-IIIa).
Blood.
1993;82:135-138
35.
Berlanga O, Bobe R, Becker M, et al.
Expression of the collagen receptor glycoprotein VI during megakaryocyte differentiation.
Blood.
2000;96:2740-2745
36.
Lagrue-Lak-Hal AH, Debili N, Kingbury G, et al.
Expression and function of the collagen receptor GPVI during megakaryocyte maturation.
J Biol Chem.
2001;276:15316-15325
37.
Zutter MM, Painter AA, Staatz WD, Tsung YL.
Regulation of alpha 2 integrin gene expression in cells with megakaryocytic features: a common theme of three necessary elements.
Blood.
1995;86:3006-3014 38. Hankenson KD, Bain SD, Kyriakides TR, Smith EA, Goldstein SA, Bornstein P. Increased marrow-derived osteoprogenitor cells and endosteal bone formation in mice lacking thrombospondin 2. J Bone Miner Res. 2000;15:851-862[CrossRef][Medline] [Order article via Infotrieve].
39.
Nagahisa H, Nagata Y, Ohnuki T, et al.
Bone marrow stromal cells produce thrombopoietin and stimulate megakaryocyte growth and maturation but suppress proplatelet formation.
Blood.
1996;87:1309-1316 40. Schattner M, Green D, Cohen I. Stromal-conditioned medium synergizes with thrombopoietin in stimulating megakaryocytopoiesis. Stem Cells. 1998;16:61-65[Medline] [Order article via Infotrieve].
41.
Lane WJ, Dias S, Hattori K, et al.
Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases.
Blood.
2000;96:4152-4159 42. Zucker-Franklin D, Stahl C, Hyde P. Megakaryocyte ultrastructure: its relationship to normal and pathologic thrombocytopoiesis. Ann N Y Acad Sci. 1987;509:25-33[CrossRef][Medline] [Order article via Infotrieve]. 43. Tavassoli M, Aoki M. Localization of megakaryocytes in the bone marrow. Blood Cells. 1989;15:3-14[Medline] [Order article via Infotrieve].
44.
Cattaneo M, Gachet C.
ADP receptors and clinical bleeding disorders.
Arterioscler Thromb Vasc Biol.
1999;19:2281-2285 45. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409:202-207[CrossRef][Medline] [Order article via Infotrieve].
46.
Italiano JE Jr, Lecine P, Shivdasani RA, Hartwig JH.
Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes.
J Cell Biol.
1999;147:1299-1312 47. Mori M, Tsuchiyama J, Okada S. Proliferation, migration and platelet release by megakaryocytes in long-term bone marrow culture in collagen gel. Cell Struct Funct. 1993;18:409-417[Medline] [Order article via Infotrieve]. 48. Behnke O, Forer A. From megakaryocytes to platelets: platelet morphogenesis takes place in the bloodstream. Eur J Haematol Suppl. 1998;61:3-23[Medline] [Order article via Infotrieve].
49.
Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA.
Consequences of GATA-1 deficiency in megakaryocytes and platelets.
Blood.
1999;93:2867-2875 50. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell. 1995;81:695-704[CrossRef][Medline] [Order article via Infotrieve].
51.
Lecine P, Villeval JL, Vyas P, Swencki B, Xu Y, Shivdasani RA.
Mice lacking transcription factor NF-E2 provide in vivo validation of the proplatelet model of thrombocytopoiesis and show a platelet production defect that is intrinsic to megakaryocytes.
Blood.
1998;92:1608-1616 52. Roth GJ. Platelets and blood vessels: the adhesion event. Immunol Today. 1992;13:100-105[CrossRef][Medline] [Order article via Infotrieve]. 53. Tsakiris DA, Scudder L, Hodivala-Dilke K, Hynes RO, Coller BS. Hemostasis in the mouse (Mus musculus): a review. Thromb Haemost. 1999;81:177-188[Medline] [Order article via Infotrieve].
54.
Savage B, Ginsberg MH, Ruggeri ZM.
Influence of fibrillar collagen structure on the mechanisms of platelet thrombus formation under flow.
Blood.
1999;94:2704-2715
55.
Nakamura T, Kambayashi J, Okuma M, Tandon NN.
Activation of the GP IIb-IIIa complex induced by platelet adhesion to collagen is mediated by both alpha2beta1 integrin and GP VI.
J Biol Chem.
1999;274:11897-11903 56. Kaplinsky C, Kenet G, Seligsohn U, Rechavi G. Association between hyperflexibility of the thumb and an unexplained bleeding tendency: is it a rule of thumb? Br J Haematol. 1998;101:260-263[CrossRef][Medline] [Order article via Infotrieve]. 57. de Paepe A. The Ehlers-Danlos syndrome: a heritable collagen disorder as cause of bleeding. Thromb Haemost. 1996;75:379-386[Medline] [Order article via Infotrieve]. 58. Bornstein P, Kyriakides TR, Yang Z, Armstrong LC, Birk DE. Thrombospondin 2 modulates collagen fibrillogenesis and angiogenesis. J Investig Dermatol Symp Proc. 2000;5:61-66[CrossRef][Medline] [Order article via Infotrieve].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  A. Eckly, C. Strassel, M. Freund, J.-P. Cazenave, F. Lanza, C. Gachet, and C. Leon Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation Blood, April 2, 2009; 113(14): 3182 - 3189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Weinbaum, T. J. Broekelmann, R. A. Pierce, C. C. Werneck, F. Segade, C. S. Craft, R. H. Knutsen, and R. P. Mecham Deficiency in Microfibril-associated Glycoprotein-1 Leads to Complex Phenotypes in Multiple Organ Systems J. Biol. Chem., September 12, 2008; 283(37): 25533 - 25543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Krady, J. Zeng, J. Yu, S. MacLauchlan, E. A. Skokos, W. Tian, P. Bornstein, W. C. Sessa, and T. R. Kyriakides Thrombospondin-2 Modulates Extracellular Matrix Remodeling during Physiological Angiogenesis Am. J. Pathol., September 1, 2008; 173(3): 879 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Mosher, L. M. Maurer, and C. Britt Carlson Secreted thrombospondin-1 controls platelet sensitivity to NO Blood, January 15, 2008; 111(2): 473 - 474. [Full Text] [PDF]
|
|
|
|
 |
|
 O. I. Stenina, E. J. Topol, and E. F. Plow Thrombospondins, Their Polymorphisms, and Cardiovascular Disease Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 1886 - 1894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. M. Ruggeri and G. L. Mendolicchio Adhesion Mechanisms in Platelet Function Circ. Res., June 22, 2007; 100(12): 1673 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Schroen, S. Heymans, U. Sharma, W. M. Blankesteijn, S. Pokharel, J. P.M. Cleutjens, J. G. Porter, C. T.A. Evelo, R. Duisters, R. E.W. van Leeuwen, et al. Thrombospondin-2 Is Essential for Myocardial Matrix Integrity: Increased Expression Identifies Failure-Prone Cardiac Hypertrophy Circ. Res., September 3, 2004; 95(5): 515 - 522. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
) and
TSP2-null (
) mice was treated with ADP (10 µm), and the
aggregation response was monitored by a change in transmittance. The
aggregation of wild-type platelets was set at 90% to correct for the
background signal obtained with platelet-poor plasma. The results are
the average of 3 independent experiments. (B) Representative tracings
of the aggregation responses of TSP2-null washed platelets
(1 × 108/mL) to thrombin (1 U/mL), collagen (10 µg/mL), and ADP (10 µm) are shown. For the latter a representative
tracing of the aggregation response of wild-type platelets (WT) is also
shown. A total of 5 mice per genotype was used to generate washed
platelets, and each experiment was repeated 4 times. (C) Representative
tracings of ATP secretion from ADP-activated blood samples from
wild-type (WT) and TSP2-null (KO) mice. The experiment was
repeated twice.
an immunohistochemical study.
J Nippon Med Sch.
2000;67:235-241